tbuckley/cabot-search huggingface dataset:
A retrospective pilot study of serum lipid levels and the risk of breast cancer
Authors: R. V. Raghupathy, C. W. Seidler, S. Emani, J. Rooney
Journal: Journal of Clinical Oncology (2006)

10539 Background: Prior prospective cohort studies have provided conflicting data regarding lipid levels as a breast cancer risk factor. These studies were either designed to study cardiovascular diseases or included a small number of incident cases. This retrospective pilot study compared the lipid profiles of breast cancer patients to a normal cohort obtained from a large community based HMO database. Methods: Fallon Clinic automated outpatient billing and laboratory databases were used to identify patients with breast cancer (ICD9–174.9) and retrieve average lipid profiles at least two years prior to the first identified diagnosis date. The outpatient billing record of a central Massachusetts HMO was used to randomly generate a control group without an ICD9 diagnosis of breast cancer. Patients were classified into two groups based on age to approximate menopausal state (pre menopausal &lt;50 yr, post menopausal ≥50 yr). T-tests were conducted to compare the total cholesterol, LDL, HDL and triglycerides of the two groups. Results: See table. Conclusions: In the pre-menopausal population, total cholesterol and LDL were significantly higher in the breast cancer group. In the post-menopausal group, triglycerides were higher and HDL lower. Though the HDL association is in concurrence with two large prior studies, other associations have not been demonstrated. An average of fasting levels obtained more than two years before diagnosis eliminates the lipid profile response to meals, variability in isolated values and influence of pre-clinical cancer on the data. However, the patients have not been matched for other breast cancer risk factors or variable menstrual phase while obtaining samples in the pre-menopausal population. [Table: see text] No significant financial relationships to disclose.
Tumor microenvironment (TME)-activatable circular aptamer-PEG as an effective hierarchical-targeting molecular medicine for photodynamic therapy
Authors: Yu Yang, Wenjun Zhu, Liang Cheng, Ren Cai, Xuan Yi, Jiaxuan He, Xiaoshu Pan, Lu Yang, Kai Yang, Zhuang Liu, Weihong Tan, Meiwan Chen
Journal: Biomaterials (2020)
POST-PROCEDURAL CARDIO-ANKLE VASCULAR INDEX IS ASSOCIATED WITH ONE-YEAR MORTALITY IN PATIENTS WHO UNDERWENT TRANS-FEMORAL TAVR
Authors: Tomohiro Yamaguchi, Kazuki Mizutani, Ryousuke Yahiro, Mana Ogawa, Tsukasa Okai, Shinichi Nonin, Asahiro Ito, Shinichi Iwata, Yasuhiro Izumiya, Yosuke Takahashi, Toshihiko Shibata, Minoru Yoshiyama
Journal: Journal of the American College of Cardiology (2020)
Freedom, Measles, and Freedom from Measles
Authors: Anne A. Gershon, Kathryn Edwards, Walter Orenstein, William Schaffner
Journal: New England Journal of Medicine (2020)

False rumors about purported dangers of vaccination continue to circulate. People who reject the scientific facts about vaccines and pathogens in favor of an emotional or faith-based choice risk the health and lives not only of their own children, but of us all.
VENTRICULAR SEPTAL ANEURYSM MIMICKING RIGHT VENTRICULAR OUTFLOW TRACT (RVOT) MASS IN A PATIENT WITH VENTRICULAR SEPTAL DEFECT (VSD)
Authors: Nikhil Mehta, Syed Rafay Ali Sabzwari, Sara Godil, Ghulam Akbar, Raman Singh Dusaj, Neeraj N. Shah
Journal: Journal of the American College of Cardiology (2020)
Clinical effectiveness of recombinant adenovirus human p53 gene combined with hyperthermia in treatment of advanced soft tissue sarcoma.
Authors: Shaowen Xiao, Shanwen Zhang
Journal: Journal of Clinical Oncology (2012)

10045 Background: Soft tissue sarcoma in advanced stage usually resist to both chemo- and radiotherapy. Several studies indicated that rAdp53 can reverse this resistance and enhance the effectiveness of radiotherapy, chemotherapy and hyperthermia. This study is to evaluate the efficacy and safety of recombinant adenovirus human p53 gene (rAdp53) combined with hyperthermia and radiation in treatment of advanced soft tissue sarcoma. Methods: From Nov. 2001 to July 2011, 30 patients with advanced soft sarcoma were enrolled in this study. All cases received hyperthermia treatment, once a week for total of 9 times, and intratumoral injection of rAdp53 at dose of 1x10 12 virus particles (vp) for 8 times. Radiation were given 48 hours after the first rAdp53 injection at a dose of 2Gy/f, five fractions a week for a total dose 16~70Gy /8~35f/2~8w, at an average of 56.3±5.3 Gy. Patients were monitored for response and adverse events. Results: The median follow-up time was 96 months. Among these patients, one case (3.3%) achieved complete response (CR), 9 (30%) cases had a partial response (PR), and 18 (60.0%) cases had a stable disease (SD). The overall clinical effectiveness rate (CR+PR+SD &gt; 6months) was 83.3.0% (25/30). One-year survival rate is 56.6% (17/30), 2-year survival rate is 23.3% (7/30), 3-year survival rate is 10.0% (3/30), and 5-year survival rate is 6.7% (2/30). Overall median survival time was 18.1 months and median TTP was 13 months. No significant adverse events were noted, except for transient fever associated with rAdp53 administration. Conclusions: rAdp53 combined with hyperthermia and radiation is effective and safe modalities in treatment of advanced soft tissue sarcoma.
NEW INSIGHTS INTO THE BENEFICIAL EFFECTS OF CARDIAC REHABILITATION: HDL CHOLESTEROL-UPTAKE CAPACITY AND PRO-RESOLVING LIPID MEDIATOR RESPONSE
Authors: Tomoyuki Honjo, Seimi Satomi-Kobayashi, Ryuji Toh, Kenji Kaihotsu, Kohei Kamemura, Kazuhiko Nakayama, Junichi Imanishi, Naoya Kuwahara, Masanori Iwahashi
Journal: Journal of the American College of Cardiology (2020)
APPROPRIATE TIMING TO CLOSE THE SESSION OF BALLOON PULMONARY ANGIOPLASTY FOR PATIENTS WITHCHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Authors: Katsushi Amemiya, Nobutaka Ikeda, Raisuke Iijima, Hidehiko Hara, Masato Nakamura
Journal: Journal of the American College of Cardiology (2020)
TRANSCATHETER LEAK OCCLUSION WITH ENDOVASCULAR COILS FOLLOWING LEFT ATRIAL APPENDAGE CLOSURE
Authors: Domenico Giovanni Della Rocca, Rodney Horton, Sanghamitra Mohanty, Luigi Di Biase, Nicola Tarantino, Mohamed Bassiouny, Amin Al-Ahmad, John Burkhardt, Carola Gianni, Ghulam Murtaza, Chintan Trivedi, Krishna Akella, Jorge Romero, David Felipe Briceno, Dhanunjaya R. Lakkireddy, Andrea Natale
Journal: Journal of the American College of Cardiology (2020)
ELECTROCONVULSIVE THERAPY INDUCED TAKOTSUBO CARDIOMYOPATHY DESPITE ANGIOTENSIN CONVERTING ENZYME INHIBITOR USE: AN INCREASING PHENOMENA
Authors: Amar Doshi, Aaron Schatz, Zackary Tushak, Jaideep Patel, Ajay Pillai, Roshi Markley
Journal: Journal of the American College of Cardiology (2020)
Abstract 10012: Beneficial Effects of Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor in Patients With Acute Myocardial Infarction
Authors: Hiroyasu Uzui, Tomohiro Shimizu, Ryouhei Nomura, Hirano Koudai, Ootake Mika, Moe Mukai, Eri Ishikawa, Akira Matsui, Daisetsu Aoyama, Yuichiro Shiomi, Naoto Tama, Hiroyuki Ikeda, Yoshitomo Fukuoka, Kanae Hasegawa, Kentaro Ishida, Kenichi Kaseno, Shinsuke Miyazaki, Hiroshi Tada
Journal: Circulation (2019)

Introduction: Low-density lipoprotein lowering therapy improve clinical outcomes in patients with cardiovascular disease. The benefit of early statin therapy has been demonstrated in acute coronary...
William M Smith
Authors: Gordon Stone, Trevor Julian, Gordon Sharp, Albert Day, Howard Stevenson
Journal: BMJ (2020)

As a medical student, William M Smith (“Bill”) was an enthusiastic member of the University Air Squadron and after graduation served with the Royal Air Force both at home in the UK and abroad, including Cyprus. In the early 1970s he was a greatly valued member of the aviation medicine training team based at RAF North Luffenham; his commanding officer at the time, commented that Bill had a significant role in establishing and developing the high standards of safety training now enjoyed by aircrew of modern high performance military aircraft. He retained a lifelong interest in and detailed knowledge of military aircraft and regularly attended reunions of those with whom he had served in the RAF.

After leaving the RAF he took over a position in a singlehanded general practice in York; this came with great challenges, but he successfully developed the practice over subsequent years. Fortuitously, his arrival in York coincided with a new appointment to an adjacent practice, also singlehanded. Over the early months of …
Cancer patients’ trade-offs for efficacy, toxicity, and cost.
Authors: Yu-Ning Wong, Brian Egleston, Kush Sachdeva, Olivia Hamilton, Naa Eghan, Melanie Pirollo, Tammy K Stump, J Robert Beck, Neal J. Meropol
Journal: Journal of Clinical Oncology (2012)

6021 Background: When making treatment decisions, cancer patients (pts) must make trade-offs between efficacy, toxicity (tox) and cost. However, little is known about how individual characteristics influence these decisions, particularly as many face high out of pocket costs. Methods: We presented cancer pts with hypothetical scenarios that asked them to choose between 2 treatments of varying levels of efficacy, tox and cost. Each scenario included 9 choice pairs. Pts were given 2 of 3 scenarios described in the Table. Tox was also varied. Demographics, cost concerns and numeracy were assessed. Within each scenario, we used latent class methods to distinguish pt groups with discrete preferences. We then used regressions with group membership probabilities as covariates to identify associations. Results: We enrolled 400 pts. Median age was 61 years (range 27-90). 63% were female. 41% were college educated. 51% had an annual income ≥$60K. 25% were enrolled at a community hospital. 98% were insured. Within each of the 3 scenarios, we identified 3 pt classes with preferences for survival or aversion to high cost or toxicity. Across each of the scenarios, &lt;6% of pts in the group averse to high cost chose the costlier treatment. &gt;92% of pts in the group that favored survival chose the highest efficacy treatment. &gt;65% of pts in the group with aversion to tox chose the lower tox treatment. Within each of the scenarios, pts in the group with preference for survival were more likely to have an income of &gt;$60K (p&lt;.05) and greater numeracy skills (p&lt;.05). In scenarios 2 and 3, pts with concerns about treatment costs were more likely to be in the class that was averse to high cost (p&lt;.05 for both). Conclusions: Even in hypothetical scenarios presented to insured pts, socioeconomic status was predictive of treatment choice. Higher income pts may be more likely to focus on survival when making decisions while those with greater cost concerns may be more likely to avoid costly treatment, regardless of survival or tox. This raises the possibility that health plans with greater cost-sharing may have the unintended consequence of increasing disparities in care. [Table: see text]
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <scp>CALGB</scp>/Alliance 50403
Authors: Lawrence D. Kaplan, Matthew J. Maurer, Wendy Stock, Nancy L. Bartlett, Noreen Fulton, Adam Pettinger, John C. Byrd, Kristie A. Blum, Ann S. LaCasce, Eric D. Hsi, Yi Tian Liu, David W. Scott, David Hurd, Amy S. Ruppert, Francisco Hernandez‐Ilizaliturri, John P. Leonard, Bruce D. Cheson
Journal: American Journal of Hematology (2020)

Abstract Immunochemotherapy followed by autologous transplant (ASCT) in CALGB/Alliance 59909 achieved a median progression‐free survival (PFS) in mantle cell lymphoma (MCL) of 5 years, but late recurrences occurred. We evaluated tolerability and efficacy of adding post‐transplant bortezomib consolidation (BC) or maintenance (BM) to this regimen in CALGB/Alliance 50403, a randomized phase II trial. Following augmented‐dose R‐CHOP/ methotrexate, high‐dose cytarabine‐based stem cell mobilization, cyclophosphamide/carmustine/etoposide (CBV) autotransplant, and rituximab, patients were randomized to BC (1.3 mg/m 2 IV days 1, 4, 8, 11 of a 3‐week cycle for four cycles) or BM (1.6 mg/m 2 IV once weekly × 4 every 8 weeks for 18 months) beginning day 90. The primary endpoint was PFS, measured from randomization for each arm. Proliferation signature, Ki67, and postinduction minimal residual disease (MRD) in bone marrow were assessed. Of 151 patients enrolled; 118 (80%) underwent ASCT, and 102 (68%) were randomized. Both arms met the primary endpoint, with median PFS significantly greater than 4 years ( P &lt; .001). The 8‐year PFS estimates in the BC and BM arms were 54.1% (95% CI 40.9%‐71.5%) and 64.4% (95% 51.8%‐79.0%), respectively. Progression‐free survival was significantly longer for transplanted patients on 50403 compared with those on 59909. Both the PFS and OS were significantly better for those who were MRD‐negative post‐induction. The high risk proliferation signature was associated with adverse outcome. Both BM and BC were efficacious and tolerable, although toxicity was significant. The comparison between studies 50403 and 59909 with long‐term follow up suggests a PFS benefit from the addition of BC or BM post‐ transplant.
Carbamazepine for the prevention of chemotherapy-induced nausea and vomiting: A pilot study using the Simon's optimal two-stage design.
Authors: Thaiana ARAGAO Santana
Journal: Journal of Clinical Oncology (2013)

e20699 Background: Nausea and vomiting have been a major drawback to patients undergoing chemotherapy. Despite standard preventive treatment, chemotherapy-induced nausea and vomiting (CINV) still occurs in approximately 50% of patients. Because of its high cost, this treatment is unavailable in centers where health assistance is provided by the government. As an effort to ameliorate prevention of CINV at lower costs, we studied the efficacy of the addition of carbamazepine to a regimen of corticosteroid plus 5-hidroxitriptamine-3 receptor antagonist for prevention of CINV as well as its side effects and influence on patients’ quality of life. Methods: This is a prospective open label phase II nonrandomized study carried out in a Brazilian public Oncology service. Patients scheduled to receive the first cycle of highly emetogenic chemotherapy were continuously recruited. Besides the current standard antiemetic treatment, patients received carbamazepine, p.o., according to the following schedule: 200 mg QD on the third day before chemotherapy; 200 mg BID on the second day before chemotherapy; 200 mg TID from one day before until the fifth day after chemotherapy. Considering sparse evidence about the anticonvulsants’ efficacy in CINV prevention, we adopted Simon’s optimal two-stage design which should include 43 patients unless overall complete prevention was not achieved in 9 out of the first 15 entries. Functional Living Index-Emesis (FLIE) questionnaire was used to measure impact on quality of life. Results: None of ten studied patients (0%) had overall complete prevention and nine needed rescue medication. Three quitted carbamazepine therapy because of somnolence and vomiting before chemotherapy infusion. Seven were able to take medication for the entire period and none were responsive, so the study was closed. There was no impact on patients´ quality of life. Conclusions: Carbamazepine was not effective for prevention of CINV and should not be used for this purpose out of experimental settings. The Simon optimal design allowed us to reach this data and stop the trial for futility, minimising the number of patients possibly exposed to an inactive agent.
Conserving Supply of Personal Protective Equipment—A Call for Ideas
Authors: Howard Bauchner, Phil B. Fontanarosa, Edward H. Livingston
Journal: JAMA (2020)

The editors of JAMA recognize the challenges, concerns, and frustration about the shortage of personal protective equipment (PPE) that is affecting the care of patients and safety of health care workers in the US and around the world.We seek creative immediate solutions for how to maximize the use of PPE, to conserve the supply of PPE, and to identify new sources of PPE.We are in-terested in suggestions, recommendations, and potential actions from individuals who have relevant experience, especially from physicians, other health care professionals, and administrators in hospitals and other clinical settings.JAMA is inviting immediate suggestions, which can be added as online comments to this article.
SEX DIFFERENCES IN PATIENTS RECEIVING LEFT VENTRICULAR ASSIST DEVICES FOR END STAGE HEART FAILURE
Authors: Jadry Gruen, Cesar Caraballo, Paul Miller, Megan McCullough, Catherine Mezzacappa, Neal Ravindra, Clancy Mullan, Nihar R. Desai, Tariq Ahmad
Journal: Journal of the American College of Cardiology (2020)
CA125 nadir as a prognostic factor in advanced ovarian carcinoma: A retrospective study of 84 patients achieving clinical CR
Authors: H. Tanabe, N. Katsumata, K. Matsumoto, S. Nishio, Y. Kato, K. Yonemori, T. Kouno, C. Shimizu, M. Ando, Y. Fujiwara
Journal: Journal of Clinical Oncology (2006)

5060 Background: There have been few reports of the relationship between CA125 nadir and the prognosis in patients with advanced ovarian carcinoma (AOC) who achieve a complete clinical response by multivariate analysis. Methods: CA125 nadir and the prognosis after the initial therapy (debulking surgery + first line chemotherapy) were retrospectively investigated in patients (pts) who had AOC meeting the criteria below and received therapy at National Cancer Center Hospital, between 1998 and 2004. The eligibility criteria were: 1) histological diagnosis of mullerian carcinoma, 2) FIGO stages III and IV, 3) a combination of platinum and taxane was administered as the first line chemotherapy, and 4) achieved clinically defined complete response (CR) after the initial therapy (ie, no cancer-related symptoms; normal physical examination, computed tomography scan of the abdomen/pelvis and chest x-ray). The possibility of CA125 nadir being a prognostic factor was investigated in pts who met these criteria by multivariate analysis (age (&lt;50 years or 50 years≤), stage (III or IV), histological type (serous adenocarcinoma (serous) or non-serous), residual tumor diameter (&lt;2 cm or 2 cm≤) and CA125 nadir (&lt;10 U/ml or 10 U/ml≤)) using the Cox regression model. Results: There were 84 pts with a median age of 55.5 years (26–74). The stage was III in 59 pts and IV in 25 pts, the histological type was serous in 71 pts and non-serous in 13pts, and the residual tumor diameter was &lt;2 cm in 72 pts and &gt;2 cm in 12 pts and the median of CA125 before the initial therapy was 535 U/ml (13–28190), the CA125 nadir was &lt;10 U/ml in 54 pts and 10 U/ml≤ in 30 pts, respectively. Regarding the prognosis, the median progression free survival (PFS) was 19 months (6–82), and the median overall survival (OS) was 36.5 months (10–82). By multivariate analysis, the CA125 nadir was significantly associated with the prognosis (hazard ratio of PFS was 0.39 (95% CI, 0.21–0.71), hazard ratio of OS was 0.28 (95% CI, 0.11–0.72)). Conclusion: CA125 nadir is a prognostic factor in patients with AOC who achieved clinically defined CR after the initial therapy, when the cut-off value was set to 10 U/ml. CA125 nadir may be an important factor for identifying pts for whom maintenance chemotherapy is effective. [Table: see text]
LEFT VENTRICULAR DIASTOLIC FUNCTION IMPROVEMENT ONE YEAR AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT FOR SEVERE AORTIC STENOSIS
Authors: Girish Pathangey, George S. Hanzel, Francis Shannon, Ivan Hanson, Wei Lau, Steven Almany, Robert D. Safian, Nathan Kerner, Michael Gallagher, Alessandro Vivacqua, Amr E. Abbas
Journal: Journal of the American College of Cardiology (2020)
SPECTRUM OF NUCLEAR PERFUSION STUDY ABNORMALITIES IN TAKOTSUBO CARDIOMYOPATHY
Authors: Jeffrey L. Anderson, Benjamin Davies Horne, Viet T. Le, Tami Bair, David Min, Santanu Biswas, C. Michael Minder, Ritesh Dhar, Steve Mason, J. Brent Muhlestein, Kirk Knowlton
Journal: Journal of the American College of Cardiology (2020)
THE SEQUELAE OF GIANT CELL MYOCARDITIS AND ITS RAPID PROGRESSION
Authors: Omar Safdar, Nicholas Ruggiero, Alec Vishnevsky, Arnold J. Greenspon, Ataul Qureshi, Matthew DeCaro, Preethi Pirlamarla, Rene Alvarez, Ilya Danelich
Journal: Journal of the American College of Cardiology (2020)
SHORT DURATIONS OF COMPRESSION HEMOSTATIC DEVICE APPLICATION POST TRANS-RADIAL CARDIAC CATHETERIZATION: THE PRACTICAL-2 TRIAL
Authors: Shahar Lavi, Shamir R. Mehta, Rehana Bajwa, Hussein Taleb, Shahrukh Nazrul Bakar, Ayaaz Sachedina, Cassandra Wagner, Amir Solomonica, Kokab Awan, Pallav Garg, Pantelis Diamantouros, Rodrigo Bagur
Journal: Journal of the American College of Cardiology (2020)
Omeprazole inhibits IgE-mediated mast cell activation and allergic inflammation induced by ingested allergen in mice
Authors: Cynthia Kanagaratham, Yasmeen S. El Ansari, Benjamin F. Sallis, Brianna-Marie A. Hollister, Owen L. Lewis, Samantha C. Minnicozzi, Michiko K. Oyoshi, Rachel Rosen, Samuel Nurko, Edda Fiebiger, Hans C. Oettgen
Journal: Journal of Allergy and Clinical Immunology (2020)
Evaluation of the knowledge of medical terminology among patients with breast cancer: A pilot study.
Authors: Monika Rucinska, Anna Kieszkowska-Grudny, Patrycja Kulita, Sergiusz Nawrocki
Journal: Journal of Clinical Oncology (2012)

e19561 Background: All breast cancer patients should receive clear information about diagnosis, treatment, its side effects and prognosis. The aim of this study was to determine the breast cancer patient knowledge about their illness and treatment. Methods: 50 breast cancer patients (30-70 years, median 58 years) were included. All patients were under radiotherapy, 48 patients were after breast conserving treatment or mastectomy, 36 patients have been treated previously by chemotherapy. All patients have been informed about their cancer, treatment and side effects and get written information. Subjects filled out a questionnaires with closed questions with 5 responses, of which one was correct, three incorrect, and the answer “I do not know”. Questions were aimed at understanding the knowledge of medical terminology, such as: neoplasm, cancer, radiotherapy, chemotherapy, side effects, itching, peeling skin, sleep disturbances, swallowing difficulties, heart rhythm disturbances, and others. Statistical analysis was done based on χ 2 test and descriptive statistics. The significance level was p&lt;0.05. Results: Not all breast cancer patients understand correctly the word cancer. There were significant differences by age: women below 50 years old answered correctly, while 47% of women between 61-70 years old did not know what cancer mean (χ 2 =18.39; p&lt;0.05). Women with primary education more often did not know what cancer is than women with secondary or higher education (χ 2 =29.60; p&lt;0.01). Correct knowledge about radiotherapy stands at 46% patients. In case of chemotherapy more than 64% of women granted the right answer. However, up 40% of patients did not know what side effects means, the majority of patients can fairly well name the various ailments, such as itching, skin’s exfoliation, sleep disorders. Significant differences were observed between the correct answers by age and education (f.ex. for itching: χ 2 =22.03; p&lt;0.01 and χ 2 =23,92; p&lt;0.05, respectively). Conclusions: Knowledge about cancer and treatment-related terms are not enough among breast cancer patients. Most varies depending on age and the level of education. Better known method of treatment is chemotherapy than radiotherapy.
LONG-TERM EVALUATION OF BIOCOMPATIBILITY AND ENDURANCE OF A NOVEL, BALLOON EXPANDABLE TRANSCATHETER POLYMERIC AORTIC VALVE IN THE OVINE AORTIC BANDING MODEL
Authors: Piotr P. Buszman, Mateusz Kachel, Wojciech Domaradzki, Carlos Fernandez, Maciej Pruski, Adam Janas, Magdalena Michalak, Krzysztof Milewski, Andrzej Bochenek, Pawel Buszman
Journal: Journal of the American College of Cardiology (2020)
PALPITATIONS IN PREGNANCY ARE NOT ALWAYS A BENIGN PRESENTATION
Authors: Kailyn Mann, Jahangir Khan, Syed Rafay Ali Sabzwari, Lekha Racharla, Amy M. Ahnert, Joanne Quinones, Yasotha Rajeswaran, Deborah Sundlof
Journal: Journal of the American College of Cardiology (2020)